☆ 4.4 Letter

Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

HAEMATOLOGICA (2015)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 100, Issue 11, Pages E446-E449

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2015.124149

Keywords

Rituximab; fludarabine; cyclophosphamide; age; prognosis; lymphoma

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.